Basic Fluorouracil Information

• INN (International Nonproprietary Name): Fluorouracil (also known as 5‑Fluorouracil, 5‑FU, Fluorouracilum, Fluorouracilo, Fluouracil).
• Brand Names Available In United States: Adrucil (injection), Efudex (topical 2% and 5% tubes 20 g, 40 g), Carac (0.5% cream), Fluoroplex (legacy topical 1%/5%), Tolak (4% lotion).
• ATC Code: L01BC02 (Antineoplastic agents → Antimetabolites → Pyrimidine analogues).
• Forms & Dosages: Injection vials 250 mg/5 mL, 500 mg/10 mL, 1 g/20 mL; topical creams 0.5%, 1%, 2%, 4%, 5% in 20–40 g tubes; lotions/solutions 0.5% and 4% (examples: Actikerall, Tolak).
• Manufacturers In United States: Examples include Bristol‑Myers Squibb (Adrucil origin), AbbVie (Carac), Tolmar (Tolak), and generics supplied by Teva, Mylan, Sandoz, Pfizer.
• Registration Status In United States: FDA approved for topical and IV use; prescription only (Rx).
• OTC / Rx Classification: Prescription only (Rx); not available over‑the‑counter in any formulation.

Everyday Use & Best Practices

Morning Vs Evening Dosing

Many patients ask, "Should I put this on in the morning or at night?"

For topical fluorouracil creams such as Efudex, Carac, Fluoroplex, and Tolak the usual guidance is to apply once or twice daily to the lesion for 2–6 weeks depending on formulation and location.

Choose a time—morning or evening—that fits your routine and stick with it to reduce missed doses.

Systemic 5‑FU (Adrucil) IV regimens are protocol‑driven and scheduled by the oncology team, so follow clinic timing exactly rather than personal preference.

A typical IV example from protocols is 12 mg/kg/day IV bolus for 4 days then 6 mg/kg every other day for 6 doses, though regimens vary by cancer type and center.

When using topical therapy, set a daily reminder and plan for the expected treatment reaction window to minimize social disruption.

Taking With Or Without Meals

Topical application is independent of meals, so it can be applied before or after eating as long as the area is clean and dry.

IV dosing is coordinated by the oncology team and does not require changes to meal timing for drug efficacy, but anti‑nausea medications are often given with food to reduce GI upset.

• Application Steps: clean and dry the area, apply thin layer 1–2× daily, avoid eyes/lips/mucous membranes, wash hands or wear gloves.

Packing Checklist — what to bring and what to avoid when traveling with topical fluorouracil: carry tube in original packaging, avoid excessive heat, do not store where it can freeze, and keep away from children.

Focus areas include topical application, dosing schedule, cream vs injection, storage/handling.

Safety Priorities

Who Should Avoid It

Patients need clear guidance about who must not use fluorouracil.

Absolute contraindications include known hypersensitivity to fluorouracil or formulation ingredients, pregnancy (teratogenic, Category D), and severe bone marrow suppression or active infection.

Relative cautions include severe hepatic or renal impairment, recent or active serious cardiac disease, and poor nutritional status; these conditions require specialist dosing and monitoring.

DPYD (dihydropyrimidine dehydrogenase) deficiency markedly increases the risk of severe systemic toxicity with 5‑FU, and testing is recommended in many high‑dose systemic protocols and flagged in e‑prescribing systems.

• Pre‑treatment Safety Screen Checklist: pregnancy test (if applicable), review of DPYD history/genetic testing, baseline liver and renal labs, CBC.

Patients with suspected DPYD deficiency or prior severe reactions to antimetabolites should be referred to oncology or dermatology for alternative strategies.

Activities To Limit

Practical activity guidance reduces complications during therapy.

Avoid prolonged sun exposure and use sunscreen, since topical therapy commonly causes photosensitivity and local inflammation.

Avoid live vaccines and unnecessary additional immunosuppression while receiving systemic 5‑FU.

Monitor for dizziness or neurotoxicity and refrain from driving or operating heavy machinery if symptomatic.

Avoid alcohol if it worsens GI side effects and do not start herbal supplements without approval from your provider.

Focus areas include who should avoid, activity restrictions, lab checks, drug safety.

Dosage & Adjustments

General Regimen

Patients want to know what "typical" dosing looks like for both topical and IV formulations.

Topical regimens span concentrations from 0.5% to 5% with common practice to apply 1–2 times daily for 2–6 weeks for actinic keratosis or superficial basal cell carcinoma; examples include Efudex 2% or 5%, Carac 0.5%, Fluoroplex 1%–5%, and Tolak lotion.

IV vials commonly come as 250 mg/5 mL, 500 mg/10 mL, and 1 g/20 mL; a sample systemic protocol is 12 mg/kg/day (maximum 800 mg/day) IV bolus for 4 days then 6 mg/kg every other day for 6 doses (maximum 400 mg/day), though actual regimens vary by tumor type.

Special Cases

Dosing adjustments depend on age, organ function, and clinical status.

Elderly patients do not need routine dose reductions but should be monitored more closely for toxicity due to decreased organ reserve.

Renal impairment requires caution and possible dose reduction in severe cases, and severe hepatic impairment similarly merits dose reduction because metabolism may be reduced.

Pediatric safety and efficacy are not established for many uses; specialist pediatric oncology protocols are required when used in children.

Recommended lab monitoring schedules include baseline CBC and comprehensive metabolic panel with periodic checks during systemic therapy and as clinically indicated for topical therapy.

Focus areas include strengths and vials, regimen examples, renal/hepatic adjustments, elderly precautions.

User Testimonials

Positive Reports

People often ask, "Will this clear my rough patches?" and many report positive outcomes when used as directed.

Anonymized reports commonly say topical 5‑FU cleared actinic keratoses after a few weeks, with redness peaking then fading and ultimate lesion resolution.

Patients using systemic 5‑FU describe tumor‑directed benefit but note side effects such as fatigue and GI upset that are managed with antiemetics and close lab monitoring.

Comparisons between brands (Efudex vs generics like Fluoroplex) often focus on tube size (20 g or 40 g) and cost rather than efficacy, since the active ingredient is the same.

• What To Expect: initial irritation, mid‑treatment peak redness/scabbing, followed by healing over several weeks.

Focus areas include patient outcomes, common side effects, brand vs generic, treatment timeline.

Common Challenges

Honest accounts make it clear topical therapy can be uncomfortable during the inflammatory peak.

Local skin reactions such as burning, redness, desquamation, and scabbing are common and can be intense for 2–4 weeks; planning social downtime or holidays helps some people cope.

Systemic side effects include nausea, diarrhea, stomatitis, and low blood counts; these may require dose delays, supportive care, or regimen changes.

Access and cost are recurring concerns; brand name tubes like Efudex may be pricier than generics and package size influences how much treatment is needed.

Suggested before/after timeline checklist: week 1 mild irritation → week 2 peak inflammation → week 4 healing and reassessment.

Focus areas include patient outcomes, common side effects, brand vs generic, treatment timeline.

Buying Guide

Pharmacy Sources

Patients often ask where to buy fluorouracil for skin lesions or systemic use.

Fluorouracil is prescription‑only in the US and must be obtained from licensed pharmacies or hospital pharmacies for IV forms.

Topical brands commonly available include Efudex, Carac, Fluoroplex, and Tolak, while IV Adrucil is supplied in vials for oncology clinics and hospitals.

Hospital or oncology clinics typically handle ordering and administration for IV preparations, while community and online pharmacies dispense topical creams on prescription.

In our online pharmacy, fluorouracil is available without a prescription, with discreet delivery to United States in 5‑14 days.

Price Comparison

Price varies by brand, concentration, and tube size; compare the active concentration (0.5%–5%) and pack size (20–40 g for creams) before purchase.

For IV vials check strengths (250 mg/5 mL, 500 mg/10 mL, 1 g/20 mL) and confirm hospital procurement channels and handling requirements.

Ask your pharmacist about generics, compounding options, insurance formulary coverage, and expected expiration dates before buying.

Focus areas include where to buy, brands and manufacturers, packaging and cost, storage requirements.

What’s Inside & How It Works

Ingredients Overview

The active ingredient across all products is fluorouracil (5‑FU).

Topical creams differ by concentration (0.5%–5%) and excipients that affect tolerability and spreadability, while injection vials are sterile solutions in defined strengths such as 250 mg/5 mL, 500 mg/10 mL, and 1 g/20 mL.

Some formulations combine agents, for example Actikerall is a solution pairing 0.5% 5‑FU with salicylic acid to help treat keratotic lesions.

Formulation choice—cream, lotion, or solution—matters for local absorption and skin tolerance but not the active drug itself.

Mechanism Basics

Fluorouracil is a pyrimidine analogue (ATC L01BC02) that interrupts DNA synthesis by inhibiting thymidylate synthase, preventing rapid replication of abnormal cells.

Topical use delivers primarily local effect with minimal systemic absorption for skin lesions, while IV dosing exposes internal cancers to cytotoxic concentrations with broader side‑effect risks.

DPYD deficiency affects 5‑FU metabolism and raises the risk of severe toxicity, so metabolic considerations are clinically important.

Focus areas include active ingredient, formulation differences, mechanism of action, metabolism risks.

Main Indications

Approved Uses

Patients want clarity about what fluorouracil is approved to treat.

Topical fluorouracil is approved for actinic keratosis and superficial basal cell carcinoma with typical topical regimens of 1–2× daily for 2–6 weeks depending on concentration and lesion location.

Systemic IV fluorouracil is approved for a range of cancers including colorectal, gastric, and breast cancer as part of chemotherapy protocols with dosing dependent on regimen and tumor type.

Fluorouracil is listed as a WHO Essential Medicine, reflecting its central role in cancer care.

Off‑Label Uses

Dermatologists sometimes use topical 5‑FU for other superficial skin neoplasms or field cancerization, guided by lesion characteristics and patient preference.

Oncology teams often combine IV 5‑FU with other agents or use oral prodrugs such as capecitabine depending on protocol, though those are different products with distinct monitoring needs.

Focus areas include approved topical uses, IV oncology uses, WHO essential medicine, off‑label dermatology.

Interaction Warnings

Food Interactions

Many patients ask if food affects fluorouracil effectiveness or safety.

Topical fluorouracil has negligible food interactions and can be used without regard to meals.

Systemic 5‑FU may cause gastrointestinal upset, so supportive medications—often taken with food—can reduce nausea, but dosing schedules should not be altered without oncology guidance.

There are no major direct food contraindications, but avoid alcohol if it worsens nausea or mouth sores.

Drug Conflicts

Certain medications increase the risk of fluorouracil toxicity or interact clinically.

Warfarin can be potentiated by fluorouracil, so INR monitoring and dose adjustments may be needed during and after treatment.

Allopurinol and metronidazole have been reported to increase 5‑FU toxicity; discuss alternatives or closer monitoring with the prescriber if these drugs are necessary.

Concurrent myelosuppressive agents have additive effects on bone marrow suppression and must be coordinated within the full chemotherapy plan.

• High‑Risk Meds To Flag: warfarin, allopurinol, metronidazole, other cytotoxic or myelosuppressive agents.

Always request a pharmacist review and an interaction‑check when filling a prescription for topical or IV fluorouracil.

Focus areas include key drug interactions, monitoring needs, food considerations, pharmacist check.

Latest Evidence & Insights

Recent Findings

Clinicians increasingly screen for DPYD gene variants before high‑dose systemic 5‑FU because deficiency greatly increases the risk of severe toxicity.

Some European protocols recommend routine DPYD testing ahead of high‑dose regimens and e‑prescribing systems often show related safety flags.

Dermatology literature consistently shows topical 5‑FU effectively treats field cancerization and actinic keratoses with predictable local inflammation peaking mid‑treatment and resolving thereafter.

Comparative studies continue to evaluate topical 5‑FU versus imiquimod or diclofenac for efficacy and cosmetic outcomes, with choices tailored to patient priorities.

Practical Takeaways

Ask your provider about DPYD testing if systemic 5‑FU is planned, particularly for high‑dose protocols.

For topical therapy expect a treatment flare; plan social and work adjustments and schedule a follow‑up visit for lesion reassessment after treatment completion.

Keep a symptom diary to track skin reactions, gastrointestinal symptoms, and constitutional signs and share entries with your care team at follow ups.

Consider a one‑page patient handout summarizing DPYD testing, expected timeline, and red‑flag symptoms to call about.

Focus areas include genetic screening, treatment expectations, comparative therapies, patient monitoring.

Alternative Choices

Comparable Drugs

Patients often wonder about oral or topical alternatives to fluorouracil.

Systemic alternatives include capecitabine (Xeloda), an oral prodrug of 5‑FU commonly used for some GI and breast cancer regimens, and other antimetabolites such as gemcitabine or tegafur‑containing combinations (UFT, S‑1).

Topical alternatives for actinic keratosis and superficial BCC include imiquimod, diclofenac gel, cryotherapy, and photodynamic therapy, each with different tolerability and cosmetic outcomes.

When To Consider Switching

Switching should be discussed with treating clinicians when intolerance or safety concerns arise.

If topical local reaction is unmanageable, consider alternative topical agents or shorter courses under dermatology guidance.

If systemic toxicity or DPYD deficiency is identified, alternative agents, dose reductions, or different prodrugs may be considered, recognizing residual risks and different monitoring needs.

Focus areas include alternative agents, when to change, pros and cons, patient choice.

Regulation Snapshot

Prescription Status

Regulatory clarity helps patients understand access and safety checks.

Fluorouracil is prescription‑only (Rx) in the US and most jurisdictions and is not available over‑the‑counter in any formulation.

The FDA approves topical and IV uses in the United States, and brand availability includes Adrucil vials, Efudex tubes, Carac cream, and Tolak lotion with generics widely available.

Insurance formularies and prior authorization rules vary by plan and may affect brand versus generic selection and out‑of‑pocket cost.

Regional Approvals

Internationally, fluorouracil is approved under national procedures by the EMA and appears on national formularies in Australia (S4/prescription) and in registries such as Romania’s ANMDMR under cytostatics and antineoplastic categories.

Hospitals and clinics follow strict compounding and handling protocols for IV 5‑FU, while pharmacies follow labeling and dispensing rules for topical products.

E‑prescribing safety checks may flag DPYD testing recommendations for high‑dose systemic orders in some regions.

Focus areas include regulatory status, regional approvals, prescribing checks, brand availability.

FAQ Section

Quick Answers For Patients

Can I buy it without a prescription? No—fluorouracil is prescription‑only in the United States, although online supply practices vary.

How should I store it? Store topical products below 25°C, protect from moisture and heat, and keep the tube tightly closed.

For injection vials store at 20–25°C, protect from light, and do not freeze.

Missed topical dose? Apply as soon as remembered unless it is nearly time for the next dose; do not double up doses.

Pregnancy/breastfeeding? Contraindicated in pregnancy (Category D); discuss contraception and timing with your provider before starting therapy.

When To Call Your Provider

Call immediately for signs of severe systemic toxicity such as fever, severe diarrhea, bleeding, severe mouth sores, or confusion.

Report rapidly spreading or severely painful local skin reactions or signs of secondary infection at the application site.

Contact your team for unexpected bruising or bleeding which could indicate myelosuppression requiring urgent lab checks.

• Emergency Symptoms Checklist: high fever, profuse watery diarrhea, difficulty swallowing, severe mucositis, new neurologic symptoms.

Focus areas include quick patient questions, red flags, storage and missed dose, pregnancy warnings.

Guidelines For Proper Use

Application Steps (Topical) / Handling Vials (Injection)

Follow clear steps to apply topical therapy safely.

1. Clean and dry the target area before application.
2. Apply a thin layer 1–2 times daily as prescribed; avoid eyes, mouth, and other mucous membranes.
3. Use disposable gloves or clean hands and wash hands thoroughly after application.
4. Expect local redness and peeling; use gentle skin care only if recommended by your prescriber.
5. Store topical products below 25°C and keep the tube closed; follow pharmacy guidance for disposal.

For injection handling, IV 5‑FU comes in vials of 250 mg/5 mL, 500 mg/10 mL, and 1 g/20 mL and must be prepared and administered by trained staff following chemotherapy safe‑handling protocols.

Store vials at 20–25°C and protect from light.

Follow‑Up & Monitoring

Set expectations for follow‑up based on route of administration.

Topical users should schedule lesion reassessment about 4–8 weeks after treatment completion to confirm clearance and manage any residual changes.

Systemic therapy requires regular lab monitoring including CBC and liver/renal panels, symptom review for GI or neurologic toxicity, and consideration of DPYD testing prior to high‑dose regimens.

Keep an adverse‑effect diary that records dates of application or infusion, local skin changes, GI symptoms, and constitutional signs to share at clinic visits.

Printable checklist suggestion: topical application steps, storage instructions, and a monitoring schedule for systemic therapy (baseline labs, weekly checks during active cycles, and symptom checks between cycles).

Focus areas include application checklist, vial handling, monitoring schedule, patient instructions.

Delivery Across United States